Platelet-activating factor enhances vascular endothelial growth factor- induced endothelial cell motility and neoangiogenesis in a murine Matrigel model

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 1, 2000, Pages 80-88

  Montrucchio, Giuseppe ^a   Lupia, Enrico ^a,b   Battaglia, Edda ^a   Del Sorbo, Lorenzo ^a   Boccellino, Mariarosaria ^a   Biancone, Luigi ^a   Emanuelli, Giorgio ^a   Camussi, Giovanni ^a,c  

^a UNIVERSITY OF TURIN   (Italy)

^b GRADENIGO HOSPITAL   (Italy)

^c Dipartimento di Medicina Interna   (Italy)

Author keywords

Angiogenesis; Platelet activating factor; Vascular endothelial growth factor

Indexed keywords

ALBUMIN; BASIC FIBROBLAST GROWTH FACTOR; BEPAFANT; IODINE 125; MATRIGEL; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; VASCULOTROPIN; [2 METHOXY 3 (N OCTADECYLCARBAMOYLOXY)PROPYL] (2 THIAZOLIOETHYL) PHOSPHATE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL GROWTH; CELL MOTILITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENDOTHELIUM CELL; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 0033964460     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.1.80     Document Type: Article

References (44)

1. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029-1039.
2. Ferrara N. Vascular endothelial growth factor. Eur J Cancer. 1996;14: 2413-2422.
3. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
4. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851-858.
5. Keck PJ, Hauser S, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to platelet derived growth factor. Science. 1989;246:1309-1311.
6. Leung DW, Cachianes G, Kuang W-J, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-1309.
7. Plouet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by At20 cells. EMBO J. 1989;8:3801-3807.
8. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Feder J. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989;84:1470-1478.
9. 2+ and von Willebrand factor release in human endothelial cells. Am J Pathol. 1991;138:213-221.
10. 3 integrin, osteopontin, and thrombin. Am J Pathol. 1996;149:293-305.
11. Wilting J, Christ B, Bokeloh M, Weich HA. In vivo effects of vascular endothelial growth factor on the chicken chorioallantoic membrane. Cell Tissue Res. 1993;274:163-172.
12. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS. 1997;79:1-8.
13. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435-439.
14. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439-442.
15. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 1999;103: 1231-1236.
16. Prescott SM, Zimmerman GA, McIntyre TM. Platelet-activating factor. J Biol Chem. 1996;268:17381-17384.
17. McManus LM, Woodard DS, Deavers SI, Pinckard RN. PAF molecular heterogeneity: pathobiological implications. Lab Invest. 1993;69: 639-650.
18. Montrucchio G, Lupia E, Battaglia E, Passerini G, Bussolino F, Emanuelli G, Camussi G, Tumor-necrosis factor α-induced angiogenesis depends on in situ platelet activating factor biosynthesis. J Exp Med. 1994;180:377-382.
19. Camussi G, Montrucchio G, Lupia E, Soldi R, Comoglio PM, Bussolino F. Angiogenesis induced in vivo by hepatocyte growth factor is mediated by platelet activating factor synthesis from macrophages. J Immunol. 1997;158:1302-1309.
20. Camussi G, Montrucchio G, Lupia E, DeMartino A, Perona L, Arese M, Vercellone A, Toniolo A, Bussolino F. Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism. J Immunol. 1995;154: 6492-6501.
21. Bussolino F, Arese M, Montrucchio G, Barra L, Primo L, Benelli R, Sanavio F, Aglietta M, Ghigo D, Rola-Pleszczynski M, Bosia A, Albini A, Camussi G. Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. J Clin Invest. 1995;96:940-952.
22. Honda Z, Nakamura M, Miki I, Minami M, Watanabe T, Seyama Y, Okado H, Toh H, Ito K, Myamoto T, Shimizu T. Cloning by functional expression of platelet activating factor receptor from guinea pig lung. Nature. 1991;349:342-346.
23. Sirois MG, Edelman ER. VEGF effect on vascular permeability is mediated by synthesis of platelet-activating factor. Am J Physiol. 1997; 41:H2746-H2756.
24. Heuer HO, Casals-Stenzel J, Muacevic G, Weber KH. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet-activating factor. J Pharmacol Exp Ther. 1990;255: 962-970.
25. Terashita Z, Tsushima S, Yoshioka S, Namoto H, Inada Y, Nishikawa K. CV 3988: a specific antagonist of platelet-activating factor (PAF-acether). Life Sci. 1983;32:1975-1982.
26. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest. 1992;67: 519-528.
27. Nachlas MM, Seligman AM. Histochemical demonstration of esterase. J Natl Cancer Inst. 1949;9:415-421.
28. Kibbey MC, Grant DS, Klieinman HK. Role of the SIKVAV site of laminin in promotion of angiogenesis and tumor growth: an in vivo Matrigel model. J Natl Cancer Inst. 1992;84:1633-1638.
29. Miles AA, Miles EM. Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs. J Physiol. 1952;118:228-257.
30. Bussolino F, Camussi G, Aglietta M, Braquet P, Bosia A, Pescarmona GP, Sanavio F, D'Urso M, Marchisio PC. Human endothelial cells are target for platelet-activating factor: platelet-activating factor induces changes in cytoskeleton structures. J Immunol. 1987;139:2439-2446.
31. Rotrosen D, Gallin JI. Histamine type I receptor occupancy increases endothelial cytosolic calcium, reduces F-actin and promotes albumin diffusion across cultured endothelial monolayers. J Cell Biol. 1986;103: 2379-2387.
32. Kueng W, Silfer E, Eppemberger U. Quantification of cell cultured on 96-well plates. Anal Biochem. 1989;182:16-19.
33. Thomas L, Randolph Byers H, Vink J, Stamenkovic I. CD-44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol. 1992; 118:971-977.
34. Romanov-Jessen L, Petersen OW. A function for filamentous α-smooth muscle actine: retardation of motility in fibroblast. J Cell Biol. 1996;134:67-80.
35. Camussi G, Bussolino F, Salvidio G, Baglioni C. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med. 1987;166:1390-1404.
36. Camussi G, Aglietta M, Malavasi F, Tetta C, Piacibello W, Sanavio F, Bussolino F. The release of platelet-activating factor from human endothelial cells in culture. J Immunol. 1983;131:2397-2403.
37. Tufano MA, Biancone L, Rossano F, Capasso C, Baroni A, De Martino A, Iorio EL, Silvestro L, Camussi G. Outer-membrane porins from Gram-negative bacteria stimulate platelet-activating factor biosynthesis by cultured human endothelial cells. Eur J Biochem. 1993;214:685-693.
38. Bligh EJ, Dyer WY. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-917.
39. Triggiani M, Hubbard WC, Chilton FH. Synthesis of 1-O-acyl-2-acetyl sn -alycero 3-phosphocholine by an enriched preparation of the human lung mast cell. J Immunol. 1990;144:4773-4780.
40. Prescott SM, McEntyre TM, Zimmerman GA. The role of platelet activating factor in endothelial cells. Thromb Haemost. 1990;64:99-103.
41. Ziehe M, Morbidelli L, Choudhuri R, Zhang H-T, Donnini S, Granger HJ. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest. 1997;99:2625-2634.
42. Collins PD, Connolly DT, Williams TJ. Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Br J Pharmacol. 1993;109:195-199.
43. Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation. 1998;97:99-107.
44. Ihida K, Predescu D, Czekay RP, Palade GE. Platelet activating factor receptor (PAF-R) is found in a large endosomal compartment in human umbilical vein endothelial cells. J Cell Sci. 1999;112:285-295.